Colistin in critically ill patients
| Autor: | Boisson M, Gregoire N, William Couet, Mimoz O |
|---|---|
| Přispěvatelé: | Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
MESH: Pharmacology
Colistin Critical Illness [SDV]Life Sciences [q-bio] MESH: Safety Drug Synergism MESH: Pharmacokinetics biochemical phenomena metabolism and nutrition MESH: Colistin [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences bacterial infections and mycoses Anti-Bacterial Agents Drug Resistance Bacterial MESH: Gram-Negative Bacteria polycyclic compounds Humans bacteria lipids (amino acids peptides and proteins) MESH: Intensive Care Units Gram-Negative Bacterial Infections |
| Zdroj: | Minerva Anestesiologica Minerva Anestesiologica, Edizione Minerva Medica, 2013, 79 (2), pp.200-8 Europe PubMed Central Scopus-Elsevier |
| ISSN: | 0375-9393 |
| Popis: | International audience; Colistin is a re-emerging old antibiotic that is used as a salvage treatment against multidrug-resistant Gram-negative infections. Because it is administrated as an inactive prodrug, colistin methanesulfonate (CMS) that undergoes rapid hydrolyze to colistin, pharmacokinetic studies using biological assays are unreliable. With the recent development of new assays using high performance liquid chromatography (HPLC) accurate pharmacokinetic of CMS and formed colistin is now available in various populations. This article aims to update previous reports on pharmacodynamics, pharmacokinetics, safety and clinical use of colistin, with a special focus on data useful to treat critically ill patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|